supp.fit

Andrographis Paniculata: study protocols

12 study groups say how much Andrographis Paniculata participants took a day. These are the doses the studies gave. They are not a recommendation.

Andrographis Paniculata: what the research found →

Dose per serving from products

28 products in our catalogue print how much Andrographis Paniculata a serving holds.

Most common: 25 mg to 50 mg, 36% of 28 products.

Dose per servingProducts
10 mg or less
1
10 mg to 25 mg
2
25 mg to 50 mg
10
50 mg to 100 mg
9
100 mg to 250 mg
0
250 mg to 500 mg
4
500 mg to 1 g
1
over 1 g
1

Dose per serving from research

12 study groups in 8 studies say how much Andrographis Paniculata participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 33% of 12 study groups.

Daily doseStudy groups
100 mg to 250 mg
2
250 mg to 500 mg
3
500 mg to 1 g
1
1 g to 2.5 g
4
2.5 g to 5 g
1
over 5 g
1

Commonly used together

None of these 12 study groups took Andrographis Paniculata with anything else.

12 study groups

Study
Use of visual analogue scale measurements (VAS) to asses the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study
1999 · Andrographis paniculata SHA-10 group · Adults of both sexes with uncomplicated common cold
1.2 g5 days79
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
2013 · A. paniculata 1,200 mg daily · Adults aged 18 years or older with mildly to moderately active ulcerative colitis
1.2 g8 weeks75
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
2013 · A. paniculata 1,800 mg daily · Adults aged 18 years or older with mildly to moderately active ulcerative colitis
1.8 g8 weeks74
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study
2016 · A. paniculata group · Adults aged 18–50 with relapsing-remitting multiple sclerosis receiving interferon beta-1a
340 mg1 year13
Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults
1991 · 3 g/day of Andrographis paniculata · Adults with pharyngotonsillitis
3 g7 days—
Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults
1991 · 6 g/day of Andrographis paniculata · Adults with pharyngotonsillitis
6 g7 days—
A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection
2010 · KalmCold · People of both sexes with uncomplicated upper respiratory tract infection
200 mg5 days—
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
2011 · HMPL-004 · Patients with mild-to-moderately active ulcerative colitis
1.2 g8 weeks—
A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis
2019 · 300 mg daily ParActin group · male and female patients with mild to moderate knee osteoarthritis, ages not reported
300 mg12 weeks—
A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis
2019 · 600 mg daily ParActin group · male and female patients with mild to moderate knee osteoarthritis, ages not reported
600 mg12 weeks—
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
2023 · AP-Bio® 200 mg/day group · Participants with uncomplicated upper respiratory tract viral infection (common cold); age and sex not reported
200 mg7 days—
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial
2023 · AP-Bio® 400 mg/day group · Participants with uncomplicated upper respiratory tract viral infection (common cold); age and sex not reported
400 mg7 days—